Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Marco Mazzoli"'
Autor:
Marco Mazzoli, Maria Angela Molinari, Manuela Tondelli, Giada Giovannini, Riccardo Ricceri, Ludovico Ciolli, Livio Picchetto, Stefano Meletti
Publikováno v:
Brain and Behavior, Vol 11, Iss 3, Pp n/a-n/a (2021)
Abstract Background Olfactory and taste disorders were reported in up to 30%–80% of COVID‐19 patients. The purpose of our study was to objectively assess smell impairment in COVID‐19 patients and to correlate olfactory function with viral recov
Externí odkaz:
https://doaj.org/article/376e942af9ca4729882806031ef2af8d
Autor:
Erika Iori, Marco Mazzoli, Alessandra Ariatti, Tiziana Salviato, Vittorio Rispoli, Franco Valzania, Giuliana Galassi
Publikováno v:
The International journal of neuroscience.
The concomitant diagnosis of Parkinson's disease (PD) and Myasthenia Gravis (MG) is rare. The aim of the study was to report our experience of patients with both diagnoses.We performed a retrospective analysis of patients with MG and PD, seen at Neur
Autor:
Francesca IACOBELLIS, Barbara SESSA, Matteo VINCENZI, Maria L. DE CICCO, Chiara ANDREOLI, Marco DI SERAFINO, Marco MAZZOLI, Benedetta RIGONI, Alessandra BRANDALISE, Andrea DELLI PIZZI, Massimo CAULO, Paolo RICCI, Anna Maria IERARDI, Michele LAPORTA, Antonio PINTO, Stefania IANNIELLO, Vittorio MIELE, Luigia ROMANO, Paolo D’ANDREA
Publikováno v:
Journal of Radiological Review. 9
Publikováno v:
Rethinking Macroeconomics with Endogenous Market Structure. :210-220
Autor:
Elisabetta Bastia, Erika Iori, Giuliana Galassi, Alessandra Ariatti, Manuela Gozzi, Alessandro Marchioni, Marco Mazzoli, Virginia Agnoletto
Publikováno v:
Neuromuscular disorders : NMD. 31(12)
About 20% of patients with myasthenia gravis (MG) may develop myasthenic crisis (MC) requiring ventilation, either invasive (MV) or non-invasive (NIV) and intensive unit care (ICU). NIV failure in patients with MC can occur up to 60% of cases admitte
Autor:
Maria Angela Molinari, Giada Giovannini, Manuela Tondelli, Ludovico Ciolli, Stefano Meletti, Marco Mazzoli, Livio Picchetto, Riccardo Ricceri
Publikováno v:
Brain and Behavior, Vol 11, Iss 3, Pp n/a-n/a (2021)
Brain and Behavior
Brain and Behavior
Background Olfactory and taste disorders were reported in up to 30%–80% of COVID‐19 patients. The purpose of our study was to objectively assess smell impairment in COVID‐19 patients and to correlate olfactory function with viral recovery. Meth
Autor:
Simone Lombardini, Marco Mazzoli
In this paper we introduce a microfounded macromodel with endogenous market structure, where macroeconomic fluctuations may be determined by firms’ strategic interactions, entry and exit. All the agents have the same preferences but may differ in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45ad3d6eebabf2224fa08dda0c228829
https://hdl.handle.net/11567/1083004
https://hdl.handle.net/11567/1083004
Autor:
Ludovico Ciolli, Maria Angela Molinari, Giada Giovannini, Riccardo Ricceri, M Tondelli, Stefano Meletti, Marco Mazzoli, Livio Picchetto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcc535ac37517062b4d79c43c6e42b67
https://doi.org/10.1002/brb3.2006/v2/response1
https://doi.org/10.1002/brb3.2006/v2/response1
Autor:
Giancarlo Garuti, Giuliana Galassi, Alessandra Ariatti, Alessandro Marchioni, Marco Mazzoli, Virginia Agnoletto, Riccardo Fantini
Publikováno v:
Acta neurologica Belgica. 121(1)
We studied 33 patients affected by juvenile and adult myotonic dystrophy type 1 (DM1). The aim of the study was to assess clinical and laboratory parameters that could predict the requirement of noninvasive ventilation (NIV) in DM1. Secondary outcome
Autor:
Giuliana Galassi, Alessandra Ariatti, Shaniko Kaleci, Franco Valzania, Paolo Frigio Nichelli, Marco Mazzoli
Publikováno v:
Acta Neurologica Belgica. 118:435-443
An unsolved issue remains whether there are clinical and immunological features to predict in a single patient the risk of conversion from ocular Myasthenia Gravis (OMG) to generalized disease (GMG) as 50-60% of patients may progress within 1-2 years